Clinical application of Huanyang Tongluo moxibustion in interventional therapy of primary hepatic carcinoma
Objective To analyze the clinical application effect and safety of Huanyang Tongluo moxibustion in interventional therapy of liver cancer.Methods Eighty patients with liver cancer admitted to Xuzhou Cancer Hospital from June 2021 to June 2023 were randomly divided into the observation group(n=40)and the control group(n=40).Both groups were treated by transcatheter hepatic arterial chemoembolization(TACE),and the observation group was treated with Huanyang Tongluo moxibustion.The changes of pain visual analogue scale(VAS),serum β-endorphin(β-EP),5-hydroxytryptamine(5-HT),Karnofsky performance status(KPS)score and core quality of life scale for cancer patients(EORTC QLQ-C30)were compared between the two groups before and after treatment,and the clinical efficacy and nausea and vomiting occurrence of the two groups were compared.Results After one month and three months of treatment,the VAS score and β-EP of the two groups decreased(P<0.05),while the 5-HT score,KPS score and EORTC QLQ-C30 score increased(P<0.05).The VAS score and β-EP in the observation group after treatment were lower than those in the control group(P<0.05),while the 5-HT score,KPS score and EORTC QLQ-C30 score were higher than those in the control group(P<0.05).After 3 months of treatment,the total effective rate of the observation group was higher than that of the control group(82.50%vs.60.00%,P<0.05).During the treatment period,the incidence and severity of nausea and vomiting in the observation group were lower than those in the control group(P<0.05).Conclusion Huanyang Tongluo moxibustion can effectively relieve patients'physical pain,improve stress and emotional function,improve activity ability and quality of life,and may be beneficial to enhance the therapeutic effect of TACE and reduce nausea and vomiting of TACE.
NETL
NSTL
万方数据
